YM BioSciences to Acquire DELEX Therapeutics

YM BioSciences, the cancer product development company, announced it has entered into a binding agreement, subject to the fulfilment of certain preconditions, in respect of the purchase of DELEX Therapeutics (Mississauga, Canada), a private clinical stage biotechnology company developing inhalation delivered fentanyl products to treat cancer pain, pursuant to which DELEX will become a wholly owned subsidiary of

YM BioSciences.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-13-2005/0003389868&EDATE=)